AbstractThe causal relation between elevated levels of LDL-C and cardiovascular disease has been largely established by experimental and clinical studies. Thus, the reduction of LDL-C levels is a major target for the prevention of cardiovascular disease. In the last decades, statins have been used as the main therapeutic approach to lower plasma cholesterol levels; however, the presence of residual lipid-related cardiovascular risk despite maximal statin therapy raised the need to develop additional lipid-lowering drugs to be used in combination with or in alternative to statins in patients intolerant to the treatment. Several new drugs have been approved which have mechanisms of action different from statins or impact on different lipoprot...
Hyperlipidaemias, multifactorial conditions partly genetically and partly life habit induced, are th...
Hyperlipidemia is a major cause of cardiovascular disease despite the availability of first-line cho...
The current step up approach in the therapy of dyslipidemias aims to reduce the amount of LDL choles...
Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD). Lowering low-density l...
High plasma levels of low density lipoproteins (LDLs) represent one of the major risk factors for ca...
Control of lipid levels is one of the most effective strategies for cardiovascular (CV) event preven...
A key strategy in preventing cardiovascular (CV) disease is the reduction of low-density lipoprotein...
Statins significantly reduce cardiovascular events by reducing low-density-lipoprotein cholesterol (...
Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has cont...
Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has cont...
Cardiovascular disease (CVD) remains a major cause of death worldwide, with dyslipidaemia playing a ...
AbstractPharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prev...
Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has con...
The need for new drugs to treat severe hypercholesterolemia is relevant because there are patients w...
AbstractAlthough statins have been used for the treatment of hypercholesterolemia for more than two ...
Hyperlipidaemias, multifactorial conditions partly genetically and partly life habit induced, are th...
Hyperlipidemia is a major cause of cardiovascular disease despite the availability of first-line cho...
The current step up approach in the therapy of dyslipidemias aims to reduce the amount of LDL choles...
Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD). Lowering low-density l...
High plasma levels of low density lipoproteins (LDLs) represent one of the major risk factors for ca...
Control of lipid levels is one of the most effective strategies for cardiovascular (CV) event preven...
A key strategy in preventing cardiovascular (CV) disease is the reduction of low-density lipoprotein...
Statins significantly reduce cardiovascular events by reducing low-density-lipoprotein cholesterol (...
Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has cont...
Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has cont...
Cardiovascular disease (CVD) remains a major cause of death worldwide, with dyslipidaemia playing a ...
AbstractPharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prev...
Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has con...
The need for new drugs to treat severe hypercholesterolemia is relevant because there are patients w...
AbstractAlthough statins have been used for the treatment of hypercholesterolemia for more than two ...
Hyperlipidaemias, multifactorial conditions partly genetically and partly life habit induced, are th...
Hyperlipidemia is a major cause of cardiovascular disease despite the availability of first-line cho...
The current step up approach in the therapy of dyslipidemias aims to reduce the amount of LDL choles...